Praticò D
Center for Experimental Therapeutics, Department of Pharmacology, University of Pennsylvania, BRB II/III, Room 812, 421, Curie Boulevard, Philadelphia, PA 19104, USA.
Ital Heart J. 2001 Dec;2(12):878-81.
Vitamin E is the most effective lipid-soluble antioxidant present in mammalian cells. The hypothesis that links vitamin E to atherogenesis postulates that oxidative modifications of unsaturated fatty acids in the low-density lipoprotein particles play a crucial role in the pathogenesis of this chronic disease. Therefore, vitamin E supplementation should reduce the extent of oxidation and, thus, be protective against atherosclerosis. This hypothesis is strongly supported by studies in murine models of atherosclerosis. In contrast, clinical trials using this vitamin have been giving a more confused picture than expected, with results ranging from a significant protective action to the absence of any effect. However, these findings do not reduce the validity of the "oxidative hypothesis" and of the large body of experimental evidence accumulated so far in its favor. Several differences between animal studies and clinical trials, and among clinical trials themselves are taken into account in order to explain the conflicting findings. Finally, insights into what might be the most appropriate nature of future trials in humans are given.
维生素E是哺乳动物细胞中最有效的脂溶性抗氧化剂。将维生素E与动脉粥样硬化形成联系起来的假说认为,低密度脂蛋白颗粒中不饱和脂肪酸的氧化修饰在这种慢性疾病的发病机制中起关键作用。因此,补充维生素E应能减少氧化程度,从而预防动脉粥样硬化。这一假说在动脉粥样硬化小鼠模型的研究中得到了有力支持。相比之下,使用这种维生素的临床试验结果比预期更加混乱,从显著的保护作用到没有任何效果不等。然而,这些发现并没有降低“氧化假说”以及迄今为止积累的大量支持该假说的实验证据的有效性。为了解释相互矛盾的研究结果,人们考虑了动物研究与临床试验之间以及临床试验本身之间的若干差异。最后,对未来人体试验最合适的性质提出了见解。